These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 24833054)

  • 1. Oncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host.
    Fournier P; Schirrmacher V
    Biology (Basel); 2013 Jul; 2(3):936-75. PubMed ID: 24833054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
    Fournier P; Bian H; Szeberényi J; Schirrmacher V
    Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro.
    Burke S; Shergold A; Elder MJ; Whitworth J; Cheng X; Jin H; Wilkinson RW; Harper J; Carroll DK
    Cancer Immunol Immunother; 2020 Jun; 69(6):1015-1027. PubMed ID: 32088771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy.
    Schirrmacher V; van Gool S; Stuecker W
    Biomedicines; 2019 Aug; 7(3):. PubMed ID: 31480379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
    Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
    J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the oncolytic potential of R
    Sharma KK; Kalyani IH; Mohapatra J; Patel SD; Patel DR; Vihol PD; Chatterjee A; Patel DR; Vyas B
    Arch Virol; 2017 Sep; 162(9):2705-2713. PubMed ID: 28578522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity.
    Huang FY; Wang JY; Dai SZ; Lin YY; Sun Y; Zhang L; Lu Z; Cao R; Tan GH
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32759233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.
    Apostolidis L; Schirrmacher V; Fournier P
    Int J Oncol; 2007 Nov; 31(5):1009-19. PubMed ID: 17912426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses elicited by ssRNA(-) oncolytic viruses in the host and in the tumor microenvironment.
    Bykov Y; Dawodu G; Javaheri A; Garcia-Sastre A; Cuadrado-Castano S
    J Cancer Metastasis Treat; 2023; 9():. PubMed ID: 37974615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of oncolytic Newcastle disease virus: a critical review.
    Tayeb S; Zakay-Rones Z; Panet A
    Oncolytic Virother; 2015; 4():49-62. PubMed ID: 27512670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
    Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
    Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus.
    Schirrmacher V
    Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Viral Knock: Ameliorating Cancer Treatment with Oncolytic Newcastle Disease Virus.
    Pathak U; Pal RB; Malik N
    Life (Basel); 2023 Jul; 13(8):. PubMed ID: 37629483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
    Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S
    BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor immunity enhancement through Newcastle viral oncolysate in mice model: A promising method to treat tumors.
    Mozaffari Nejad AS; Fotouhi F; Mehrbod P; Alikhani MY
    Saudi J Biol Sci; 2021 Oct; 28(10):5833-5840. PubMed ID: 34588898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The oncolytic Newcastle disease virus as an effective immunotherapeutic strategy against glioblastoma.
    Cuoco JA; Rogers CM; Mittal S
    Neurosurg Focus; 2021 Feb; 50(2):E8. PubMed ID: 33524945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.
    Schierer S; Hesse A; Knippertz I; Kaempgen E; Baur AS; Schuler G; Steinkasserer A; Nettelbeck DM
    Int J Cancer; 2012 Apr; 130(7):1682-94. PubMed ID: 21557217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus.
    Pfirschke C; Schirrmacher V
    Int J Oncol; 2009 Apr; 34(4):951-62. PubMed ID: 19287952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.